Clinical evaluation of moxifloxacin on acute exacerbation of chronic obstructive pulmonary disease in elderly patients
Pan Pan
Abstract
Pan Pan
Abstract
Objective: To evaluate the efficiency and safety of moxifloxacin on acute exacerbation of chronic obstructive pulmonary disease(AECOPD) in elderly patients.Methods: Seventy-eight elderly patients with AECOPD were randomly divided into observation group and control group.In control group,38 patients were treated with levofloxacin at 0.4g,intravenous infusion,one time per day;The 40 patients in observation group were treated with moxifloxacin at 0.4g,intravenous infusion,one time per day;the treatment lasted 7 14 days in the two group,the total effective rate、bacterial eradication rate and drug reaction were compared between the two groups.Results: In moxifloxacin group,the effective rate was 87.5%,in levofloxacin group,the effective rate was 73.7%,there had statistical differences(P 0.05).The bacterial eradication rate and adverse drug reaction rate were 90.5% and 7.5% in moxifloxacin group vs 58.8% and 10.5% in levofloxacin group,which had no statistical differences(P 0.05).Conclusions: Moxifloxacin is an effective and safe drug in treatment of AECOPD in elderly patients.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective: To evaluate the efficiency and safety of moxifloxacin on acute exacerbation of chronic obstructive pulmonary disease(AECOPD) in elderly patients.Methods: Seventy-eight elderly patients with AECOPD were randomly divided into observation group and control group.In control group,38 patients were treated with levofloxacin at 0.4g,intravenous infusion,one time per day;The 40 patients in observation group were treated with moxifloxacin at 0.4g,intravenous infusion,one time per day;the treatment lasted 7 14 days in the two group,the total effective rate、bacterial eradication rate and drug reaction were compared between the two groups.Results: In moxifloxacin group,the effective rate was 87.5%,in levofloxacin group,the effective rate was 73.7%,there had statistical differences(P 0.05).The bacterial eradication rate and adverse drug reaction rate were 90.5% and 7.5% in moxifloxacin group vs 58.8% and 10.5% in levofloxacin group,which had no statistical differences(P 0.05).Conclusions: Moxifloxacin is an effective and safe drug in treatment of AECOPD in elderly patients.
Key concepts: Moxifloxacin, Medicine, Levofloxacin, Exacerbation, COPD, Internal medicine, Pulmonary disease, Adverse effect